Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*-Reference-Cited by-同舟云学术

Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*

Published:2022-10-10 Issue:12 Volume:50 Page:1788-1798
ISSN:0090-3493
Container-title:Critical Care Medicine
language:en
Short-container-title:

Author:

Carvelli Julien,Meziani Ferhat,Dellamonica Jean,Cordier Pierre-Yves,Allardet-Servent Jerome,Fraisse Megan,Velly Lionel,Barbar Saber Davide,Lehingue Samuel,Guervilly Christophe,Desgrouas Maxime,Camou Fabrice,Piperoglou Christelle,Vely Frederic,Demaria Olivier,Karakunnel Joyson,Fares Joanna,Batista Luciana,Rotolo Federico,Viotti Julien,Boyer-Chammard Agnes,Lacombe Karine,Le Dault Erwan,Carles Michel,Schleinitz Nicolas,Vivier Eric,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

Reference29 articles.

1. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: A nationwide, population-based retrospective cohort study.;Piroth;Lancet Respir Med,2021

2. Impact of ICU transfers on the mortality rate of patients with COVID-19: Insights from comprehensive national database in France.;Sanchez;Ann Intensive Care,2021

3. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia.;Grant;Nature,2021

4. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets.;Delorey;Nature,2021

5. The spatial landscape of lung pathology during COVID-19 progression.;Rendeiro;Nature,2021

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study;JID Innovations;2024-11

2. Local complement activation and modulation in mucosal immunity;Mucosal Immunology;2024-08

3. Immune checkpoint inhibitors and SARS-CoV2 infection;International Immunopharmacology;2024-08

4. Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Diffuse Alveolar Hemorrhage With Avacopan;ACR Open Rheumatology;2024-07-30

5. Antibody drugs targeting SARS-CoV-2: Time for a rethink?;Biomedicine & Pharmacotherapy;2024-07